NEW YORK, Sept. 16, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sizmek, Inc. (“Sizmek” or the “Company”) (Nasdaq: SZMK) in the United States District Court for the Western District of Texas on behalf of current stockholders of Sizmek, seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that the Board of Directors of Sizmek breached their fiduciary duties by causing a materially incomplete and misleading Recommendation Statement (the “Recommendation Statement”), to be filed with the SEC. The Complaint further alleges that merger consideration Sizmek stockholders will receive in connection with the transaction does not reflect the fair value of Sizmek shares.
If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel
Samsung Shares Drop as Labor Union Confirms Planned Strike
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks
Samsung Faces Major Strike Threat as Union Restarts Pay Talks
TrumpRx Expands Discount Drug Access With 600 Generic Medications 



